HWN Suggests

Anticoagulation in Distal DVT

A recent review article (which includes data from CACTUS) offers two suggestions:

The most conservative management will still be anticoagulation of the isolated DDVT. This should be standard for patients with cancer or other pro-thrombotic state that would place the patient at high risk for the development of DVT. Deferred anticoagulation with follow up ultrasound can be used for patients without significant thrombotic risk factors. You can engage in shared decision making and discuss the risks for bleeding in your patient against the 4-5% risk for clot progression and 1% risk for PE (based on the CACTUS trail as well as retrospective data).

If you decide against anticoagulation…

read full article

Featured

 Endovascular Treatment for Lower Extremity Deep Vein Thrombosis: An Overview

Various endovascular procedures have been developed in the recent years to treat DVT, and endovascular treatment has been established as one of the major therapeutic methods to treat lower extremity DVT. However, the treatment of lower extremity DVT varies according to the disease duration, location of affected vessels, and the presence of symptoms.

 How to treat isolated distal deep vein thrombosis

Unlike in proximal DVT, the optimal therapeutic management of IDDVT remains uncertain. In clinical practice, the vast majority of IDDVT patients are managed with anticoagulation rather than with surveillance serial compression ultrasonography, which tends to be reserved to individuals at a high bleeding risk. Available data seem to favor anticoagulant therapy over no anticoagulation, thanks to a significant reduction in the risk for proximal extension and recurrence, without increased bleeding risk.

Articles of Interest

Cochrane Library

Our review found a benefit for people with distal DVT treated with anticoagulation therapy with little or no clear difference in major bleeding events, although there was an increase in clinically relevant non‐major bleeding when compared with no treatment or placebo. The small number of participants in this meta‐analysis and strength of evidence suggests more research regarding the treatment of distal DVT is needed. Randomised controlled trials comparing different treatments and different treatment periods with placebo or compression therapy are required.

Don’t Skimp on Anticoagulation in Isolated Distal DVT

If you opt to anticoagulate these patients, you should do so for 12 weeks and not 6 weeks, experts say.

Emergency Department Management of Suspected Calf-Vein Deep Venous Thrombosis: A Diagnostic Algorithm

Treatment is controversial: universal versus selective anticoagulation. The risks of proximal progression and life-threatening embolization should be considered along with the generally more benign natural history of distal clots and an individual patient’s risk factors for both clot propagation and the complications of therapy.

How I treat isolated distal deep vein thrombosis (IDDVT)

Thromboses limited to infrapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed in subjects with suspected pulmonary embolism or DVT and account for one-fourth to one-half of all diagnosed leg DVTs. Despite their frequency, the natural history of IDDVTs and their real risk of thromboembolic complications are still uncertain because of the scarcity of prospective, blind, nonintervention studies.

How should patients with post-operative distal DVT be managed?

Distal DVT can either be treated immediately upon diagnosis (with anticoagulation) or be monitored (by holding anticoagulation and only treating progression to proximal veins or if PE is identified). Data suggesting that anticoagulation is indicated for distal DVT are limited, and such a strategy entails a risk of over-treatment when weighed against the risks of anticoagulation in the postoperative setting.

Management of Isolated Calf DVTs with Anticoagulation

The management of DVTs isolated to the calf veins has remained a controversial topic for many years. The 2008 guidelines produced by the American College of Chest Physicians (ACCP) recommended long-term (3 month) anticoagulation for all patients with DVT, regardless of proximal extension. Updated ACCP guidelines produced this year, on the other hand, make no specific recommendation, offering options of either treating or not treating isolated calf DVTs, as long as surveillance ultrasounds are performed. This lack of a firm recommendation seems based less on actual evidence, as it is on the low quality of evidence,

Should Patients with Distal DVT Receive Pharmacologic Therapy?

Although the number of patients in these studies was small (relative to disease burden), the analysis and outcomes provide valuable new evidence that — in addition to high-risk patients — many low-risk patients with distal DVT should receive anticoagulants. The only anticoagulant studied was warfarin, but using direct-acting oral anticoagulants (DOACs) for patients with distal DVT seems appropriate.

Treatment of below-the-knee deep vein thrombosis

Our review found a benefit for people with distal DVT treated with anticoagulation therapy with little or no clear difference in major bleeding events, although there was an increase in clinically relevant non-major bleeding when compared with no treatment or placebo. The small number of participants in this meta-analysis and strength of evidence suggests more research regarding the treatment of distal DVT is needed. Randomised controlled trials comparing different treatments and different treatment periods with placebo or compression therapy are required.

Treatment of distal deep vein thrombosis

The treatment of distal (below the knee) deep vein thrombosis (DVT) is not clearly established. Distal DVT can either be treated with anticoagulation, or monitored with close follow‐up to detect progression to the proximal veins (above the knee), which requires anticoagulation. Proponents of this monitoring strategy base their decision to withhold anticoagulation on the fact that progression is rare and most people can be spared from potential bleeding and other adverse effects of anticoagulation.

Treatment of Distal DVT

The term VTE encompasses a spectrum of disease ranging from mild calf symptoms from DVT to life-threatening cardiopulmonary collapse from PE. Isolated distal DVT is a subset of VTE with decreased risk of recurrent DVT and PE, compared with more proximal disease. A strategy of close observation may be appropriate in those with isolated distal DVT given the lower risk of complications.

Resources

The NNT

Based on the existing data, anticoagulation was associated with a reduced rate of recurrent VTE with no significant increase in the risk of major bleeding compared to placebo or no intervention. However, given the limitations of the specific studies and need to individualize patient-oriented risks and benefits, we have assigned a color recommendation of Yellow (unclear if benefits) to this intervention. Further study is needed with larger sample sizes, patients taking DOACs for treatment of distal DVT, and other populations including those with cancer-associated or recurrent distal DVTs.